White House Anti-Fraud Roundtable Draws Partisan Divide Over Access

The Trump administration moved to advance measures aimed at reducing prescription drug costs while convening a roundtable on anti-fraud efforts led by Vice President JD Vance. The event highlighted ongoing federal priorities but exposed tensions in state-federal cooperation on enforcement.

Democratic attorneys general from two dozen states declined to attend the roundtable, citing short notice and the absence of a detailed agenda in correspondence sent to Vance. Several instead directed senior staff from their offices to participate after RSVPing. Officials from California, New York, New Jersey, Minnesota, Massachusetts, Maryland and Nevada were subsequently denied entry, according to statements from New York Attorney General Letitia James and California Attorney General Rob Bonta.

James said the reasons provided for the exclusions varied and appeared inconsistent. She noted that the excluded staff members had handled complex fraud cases, secured criminal convictions and reached settlements worth millions of dollars. Bonta stated that the Democratic officials would not serve as props in a political event. The White House has not issued a public response detailing the criteria used to admit or exclude participants.

The roundtable itself focused on state-level anti-fraud initiatives and was attended by Republican attorneys general. Separate administration actions on drug pricing were referenced in the broader context of the day's announcements but received no further elaboration in the roundtable coverage. No independent confirmation has emerged regarding the precise number of staff members turned away or the internal decision process for access.